X4 Pharmaceuticals Shares Outstanding History (XFOR)
X4 Pharmaceuticals reported 90.9M shares outstanding at the end of fiscal 2025.
View full X4 Pharmaceuticals company overviewX4 Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 90.9M | 85.2M | +1495.35% |
| 2024 | 2024-12-31 | 5.7M | 122,658.986 | +2.20% |
| 2023 | 2023-12-31 | 5.6M | 1.5M | +37.62% |
| 2022 | 2022-12-31 | 4.1M | 3.1M | +332.55% |
| 2021 | 2021-12-31 | 936,650.978 | 393,670.136 | +72.50% |
| 2020 | 2020-12-31 | 542,980.842 | 5,889.738 | +1.10% |
| 2019 | 2019-12-31 | 537,091.105 | 525,381.093 | +4486.60% |
| 2018 | 2018-12-31 | 11,710.012 | −67,639.681 | −85.24% |
| 2017 | 2017-12-31 | 79,349.692 | — | — |
X4 Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 96.1M | 88.2M | +1107.48% |
| Q1 2026 | 2026-03-31 | 94.3M | 94.1M | +48829.83% |
| Q4 2025 | 2025-12-31 | 90.9M | 90.7M | +47808.51% |
| Q3 2025 | 2025-09-30 | 25.1M | 19.5M | +348.13% |
| Q2 2025 | 2025-06-30 | 8.0M | 2.4M | +42.12% |
| Q1 2025 | 2025-03-31 | 192,765.209 | −5.4M | −96.55% |
| Q4 2024 | 2024-12-31 | 189,751.092 | −5.4M | −96.60% |
| Q3 2024 | 2024-09-30 | 5.6M | 126,724.882 | +2.31% |
| Q2 2024 | 2024-06-30 | 5.6M | 125,813.028 | +2.30% |
| Q1 2024 | 2024-03-31 | 5.6M | 1.5M | +37.42% |
| Q4 2023 | 2023-12-31 | 5.6M | 1.5M | +37.62% |
| Q3 2023 | 2023-09-30 | 5.5M | 3.2M | +139.63% |
| Q2 2023 | 2023-06-30 | 5.5M | 4.4M | +430.53% |
| Q1 2023 | 2023-03-31 | 4.1M | 3.0M | +296.66% |
| Q4 2022 | 2022-12-31 | 4.1M | 3.1M | +332.55% |
| Q3 2022 | 2022-09-30 | 2.3M | 1.5M | +178.18% |
| Q2 2022 | 2022-06-30 | 1.0M | 213,331.122 | +26.06% |
| Q1 2022 | 2022-03-31 | 1.0M | 245,855.465 | +31.52% |
| Q4 2021 | 2021-12-31 | 936,650.978 | 393,670.136 | +72.50% |
| Q3 2021 | 2021-09-30 | 822,800.609 | 280,455.331 | +51.71% |
| Q2 2021 | 2021-06-30 | 818,675.771 | 281,151.567 | +52.30% |
| Q1 2021 | 2021-03-31 | 780,100.086 | 243,008.981 | +45.25% |
| Q4 2020 | 2020-12-31 | 542,980.842 | 128,855.216 | +31.12% |
| Q3 2020 | 2020-09-30 | 542,345.279 | 128,457.68 | +31.04% |
| Q1 2020 | 2020-03-31 | 537,524.204 | 313,597.988 | +140.05% |
| Q4 2019 | 2019-12-31 | 537,091.105 | 535,139.046 | +27414.08% |
| Q3 2019 | 2019-09-30 | 414,125.627 | 334,659.211 | +421.13% |
| Q2 2019 | 2019-06-30 | 413,887.598 | 334,421.182 | +420.83% |
| Q1 2019 | 2019-03-31 | 223,926.216 | 144,576.313 | +182.20% |
| Q4 2018 | 2018-12-31 | 1,952.059 | −77,397.633 | −97.54% |
| Q3 2018 | 2018-09-30 | 79,466.416 | — | — |
| Q2 2018 | 2018-06-30 | 79,466.416 | — | — |
| Q1 2018 | 2018-03-31 | 79,349.903 | — | — |
| Q4 2017 | 2017-12-31 | 79,349.692 | — | — |
X4 Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, X4 Pharmaceuticals's shares outstanding moved from 542,980.842 to 90.9M, a change of 90.4M. The latest reported quarter, Q2 2026, shows 96.1M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review X4 Pharmaceuticals filings at SEC.gov ↗